• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Bausch Health's Aesthetic Business, Solta Medical, Earns Prestigious Trademark Certification of Thermage® in China

    5/28/26 4:15:00 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BHC alert in real time by email

    Thermage®, a pioneer in non-invasive skin tightening, was awarded the AAA Well-Known Trademark Certification, the highest recognition in China's domestic trademark evaluation system.

    LAVAL, QC, May 28, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and Solta Medical, a global leader in the medical aesthetics market, are proud to announce that their flagship brand, Thermage®, was awarded the prestigious AAA Well-Known Trademark Certification ("AAA") by the China Trademark Association (CTA), a renowned accreditation reserved for top-tier brands. This elite distinction—earned by only 217 brands across mainland China—recognizes Thermage's exceptional brand reputation, consumer confidence, and market influence.

    "Joining an elite group of only 217 brands nationwide, this distinction cements Thermage's position as a leader in medical aesthetics and is a powerful validation of the reliability and confidence we have established with consumers and practitioners in China," said Thomas J. Appio, CEO of Bausch Health. "It underscores our commitment to innovation with the highest standards of quality and safety."

    "With over a decade of presence in China, and over 5 million treatments performed worldwide, Thermage® has earned its reputation as a leader in non‑invasive aesthetic treatments," said Jiny Kim, Senior Vice President, Solta Medical, Bausch Health. "The AAA rating serves as a credible "mark of trust," allowing consumers to choose Thermage® with confidence in its legitimacy and product integrity."

    About Thermage® FLX system

    INDICATIONS

    • The radiofrequency energy only delivery components of the Thermage® FLX system and accessories are indicated for use in:
      • Dermatologic and general surgical procedures for electrocoagulation and hemostasis
      • Non-invasive treatment of wrinkles around the eyes, including upper and lower eyelids
      • Non-invasive treatment of wrinkles
    • The simultaneous application of radiofrequency energy and skin vibration by the Thermage® FLX system and accessories are indicated for use in:
      • Dermatologic and general surgical procedures for electrocoagulation and hemostasis
      • Non-invasive treatment of wrinkles around the eye
      • Non-invasive treatment of wrinkles
      • Temporary improvement in the appearance of cellulite
      • Relief of minor muscle aches and pain
      • Relief of muscle spasms
      • Temporary improvement of local circulation (blood circulation)

    IMPORTANT SAFETY INFORMATION

    • Do not undergo Thermage® treatment if you have a cardiac pacemaker, a cardioverter, a defibrillator, or any other electrical implant. Let your doctor know if you have an electrical implant or if you have any questions about whether you should undergo a Thermage® treatment.
    • Solta Medical has not studied the use of the Thermage® system:
      • Over skin fillers (lips, cheeks, facial wrinkles and skin folds)
      • In people who are pregnant and/or breast feeding, diabetic, have an auto-immune disease such as lupus, have cold sores, have genital herpes, or have epilepsy
      • In people who have permanent make-up and/or tattoos
      • In children
    • The most commonly reported adverse effect during treatment is mild to moderate pain in the area being treated.
      • The most commonly reported adverse effects after treatment include the following:
      • Mild redness may occur and typically resolves within 24 hours.
      • Swelling may occur and typically resolves within 5 days but can remain up to several weeks.
      • The following adverse effects occur infrequently:
        • The procedure may produce heating in the upper layers of the skin, causing burns and subsequent blister and scab formation. There is a possibility of scar formation.
        • Skin surface irregularities may appear up to 1 or more months post-treatment.
        • Numbness, tingling" or temporary paralysis may occur; typically resolves in a short period of time but may persist up to several weeks.
        • Lumps or nodules may occur under the skin primarily in the neck area, and usually resolve within 1 or 2 weeks without chronic or long-term complications.
        • Skin may darken, but normally resolves within several months.

    Talk to your doctor for more information about Thermage® and see thermage.com for additional details.

    About Bausch Health

    Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global, diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb Corporation. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. Our aesthetic business, Solta Medical, is a global leader in the aesthetics market, whose vision is to develop and support trusted aesthetic brands that provide value to our customers and patients. More information about Solta Medical can be found at www.solta.com. For more information about Bausch Health, visit www.bauschhealth.com and connect with us on LinkedIn.

    Forward-looking Statements

    This news release may contain forward-looking statements within the meaning of applicable securities laws, including the Safe Harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may generally be identified by the use of the words "will," "anticipates," "hopes," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "subject to" and variations or similar expressions. These statements are neither historical facts nor assurances of future performance, are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Actual results are subject to other risks and uncertainties that relate more broadly to Bausch Health's overall business, including those more fully described in Bausch Health's most recent annual and quarterly reports and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. The Company undertakes no obligation to update any of these forward-looking statements to reflect events, information or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

    Investor Contact:

    Media Contact:

    Garen Sarafian

    Katie Savastano

    ir@bauschhealth.com

    corporate.communications@bauschhealth.com

    (877) 281-6642 (toll free)

    (908) 569-3692





    BHC-PRODUCTS

     

    Bausch Health logo (PRNewsfoto/Bausch Health Companies Inc.)

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/bausch-healths-aesthetic-business-solta-medical-earns-prestigious-trademark-certification-of-thermage-in-china-302784868.html

    SOURCE Bausch Health Companies Inc.

    Get the next $BHC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BHC

    DatePrice TargetRatingAnalyst
    12/9/2025$8.00Equal Weight
    Barclays
    8/2/2024$9.00 → $3.00Neutral → Underweight
    Piper Sandler
    7/10/2024$8.00Mkt Perform
    Raymond James
    9/20/2023$9.00 → $16.00Hold → Buy
    Jefferies
    6/16/2023Outperform → Market Perform
    TD Cowen
    7/29/2022Buy → Hold
    Truist
    7/29/2022$12.00 → $5.00Outperform → Sector Perform
    RBC Capital Mkts
    7/28/2022Overweight → Neutral
    JP Morgan
    More analyst ratings

    $BHC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Bausch Health's Aesthetic Business, Solta Medical, Earns Prestigious Trademark Certification of Thermage® in China

    Thermage®, a pioneer in non-invasive skin tightening, was awarded the AAA Well-Known Trademark Certification, the highest recognition in China's domestic trademark evaluation system.LAVAL, QC, May 28, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and Solta Medical, a global leader in the medical aesthetics market, are proud to announce that their flagship brand, Thermage®, was awarded the prestigious AAA Well-Known Trademark Certification ("AAA") by the China Trademark Association (CTA), a renowned accreditation reserved for top-tier brands. This elite distinction—earned by only 217 brands across mainland China—recognizes

    5/28/26 4:15:00 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bausch Health Announces 2026 Annual Meeting of Shareholder Results

    LAVAL, QC, May 19, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that shareholders elected all 10 director nominees at its 2026 Annual Meeting of Shareholders ("Annual Meeting") held on May 19, 2026, including Eiry W. Roberts, M.D., who was elected as a new director. Dr. Roberts brings extensive pharmaceutical leadership experience, including expertise in clinical development, medical strategy and business development, and previously served as Chief Medical Officer of Neurocrine Biosciences, Inc. Dr. Roberts will serve as chair of the Science and Technology Committee.Detailed results of the vote follow:NameForWithheldBroker Non-VotesThomas J. Appio196,

    5/19/26 4:15:00 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bausch Health to Participate in RBC Capital Markets 2026 Global Healthcare Conference

    LAVAL, QC, May 13, 2026 /CNW/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that Thomas J. Appio, Chief Executive Officer, and Jean-Jacques Charhon, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the RBC Capital Markets 2026 Global Healthcare Conference in New York City on Wednesday, May 20, 2026. A live audio webcast of the event will be accessible on the Investor Relations section of Bausch Health's website.DetailsDate:        Wednesday, May 20, 2026Time:        9:30 a.m. U.S. ETWebcast:  http://ir.bauschhealth.com/events-and-presentationsA replay of the event will be available on the investor relations website following t

    5/13/26 7:00:00 AM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHC
    SEC Filings

    View All

    SEC Form SD filed by Bausch Health Companies Inc.

    SD - Bausch Health Companies Inc. (0000885590) (Filer)

    6/1/26 4:06:14 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bausch Health Companies Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Bausch Health Companies Inc. (0000885590) (Filer)

    5/19/26 4:18:10 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bausch Health Companies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Bausch Health Companies Inc. (0000885590) (Filer)

    4/29/26 4:10:14 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Bausch Health with a new price target

    Barclays initiated coverage of Bausch Health with a rating of Equal Weight and set a new price target of $8.00

    12/9/25 8:43:03 AM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bausch Health downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Bausch Health from Neutral to Underweight and set a new price target of $3.00 from $9.00 previously

    8/2/24 7:25:50 AM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Raymond James initiated coverage on Bausch Health with a new price target

    Raymond James initiated coverage of Bausch Health with a rating of Mkt Perform and set a new price target of $8.00

    7/10/24 8:35:33 AM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Wechsler Amy B was granted 45,871 shares, increasing direct ownership by 17% to 313,585 units (SEC Form 4)

    4 - Bausch Health Companies Inc. (0000885590) (Issuer)

    5/26/26 7:05:06 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Roberts Eiry was granted 45,871 shares (SEC Form 4)

    4 - Bausch Health Companies Inc. (0000885590) (Issuer)

    5/26/26 7:02:25 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Power Robert N was granted 45,871 shares, increasing direct ownership by 18% to 300,594 units (SEC Form 4)

    4 - Bausch Health Companies Inc. (0000885590) (Issuer)

    5/26/26 7:00:09 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Paulson & Co. Inc. bought $15,625,000 worth of shares (2,500,000 units at $6.25) (SEC Form 4)

    4 - Bausch Health Companies Inc. (0000885590) (Issuer)

    11/28/25 5:38:39 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Paulson John bought $312,490,062 worth of shares (34,721,118 units at $9.00) (SEC Form 4)

    4 - Bausch Health Companies Inc. (0000885590) (Issuer)

    8/14/25 9:35:28 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Paulson John bought $21,267,731 worth of shares (3,243,049 units at $6.56) (SEC Form 4)

    4 - Bausch Health Companies Inc. (0000885590) (Issuer)

    8/13/25 6:51:24 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHC
    Leadership Updates

    Live Leadership Updates

    View All

    Bausch Health Announces 2026 Annual Meeting of Shareholder Results

    LAVAL, QC, May 19, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that shareholders elected all 10 director nominees at its 2026 Annual Meeting of Shareholders ("Annual Meeting") held on May 19, 2026, including Eiry W. Roberts, M.D., who was elected as a new director. Dr. Roberts brings extensive pharmaceutical leadership experience, including expertise in clinical development, medical strategy and business development, and previously served as Chief Medical Officer of Neurocrine Biosciences, Inc. Dr. Roberts will serve as chair of the Science and Technology Committee.Detailed results of the vote follow:NameForWithheldBroker Non-VotesThomas J. Appio196,

    5/19/26 4:15:00 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bausch Health Appoints New Chief Medical Officer and Head of R&D

    LAVAL, QC / ACCESSWIRE / December 2, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is pleased to announce the appointment of Jonathan Sadeh M.D., M.Sc as Executive Vice President, Chief Medical Officer and Head of R&D. This strategic addition to our leadership team underscores our commitment to innovation, excellence, and enriching lives.Jonathan brings a wealth of experience and a proven track record of success both as a physician-scientist and a leader in the pharmaceutical industry. With over 20 years of expertise in clinical research and drug development, he has consistently demonstrated the ability to drive growth and foster innovation. Most recently, at Bristol-Meyers Squibb,

    12/2/24 8:00:00 AM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bausch Health Welcomes Two New Members to the Executive Leadership Team

    LAVAL, QC / ACCESSWIRE / July 19, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced the appointment of two new members to its Executive Leadership Team (ELT).Jean-Jacques Charhon ("JJ") will join the Company as Chief Financial Officer on August 19, 2024. JJ has over 25 years of experience in financial leadership roles with public and private companies across healthcare, high tech and services, primarily at General Electric, Hewlett Packard, Novartis and Purdue Pharma. Upon JJ's arrival, John Barresi, the Company's Interim Chief Financial Officer, will resume his role as SVP, Controller.Aimee Lenar joined the Company on July 15, 2024 as Executive Vice President, US Pharm

    7/19/24 7:00:00 AM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHC
    Financials

    Live finance-specific insights

    View All

    BAUSCH HEALTH ANNOUNCES FIRST QUARTER 2026 RESULTS

    First Quarter Consolidated Revenues of $2.52 billion, up 12% on a Reported basis and 7% on an Organic (non-GAAP)1 basis over the prior year periodGAAP Net Loss Attributable to Bausch Health of $1,423 million and GAAP Net Loss of $1,431 million, inclusive of a $1,426 million goodwill impairment chargeGAAP Loss per Share of ($3.82) (basic and diluted) compared to ($0.16) in the prior year periodAdjusted Earnings per Diluted Share (non-GAAP) of $0.78 compared to $0.59 in the prior year period, an increase of 32%Consolidated Adjusted EBITDA Attributable to Bausch Health (non-GAAP)1 of $837 million, up 27% on a Reported basis over the prior year periodBAUSCH HEALTH EXCLUDING BAUSCH + LOMB FIRST Q

    4/29/26 4:05:00 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bausch Health to Announce First Quarter 2026 Results on April 29, 2026

    LAVAL, QC, March 31, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release first quarter 2026 financial results after market close on Wednesday, April 29, 2026. Bausch Health will host a live conference call and webcast at 5:00 p.m. U.S. EDT to discuss results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call.Conference Call DetailsDate:                                            Wednesday, April 29, 2026Time:                                            5:00 p.m. U.S. EDTWebcast:                                      http://ir.bauschhealth.com/events-and-

    3/31/26 7:00:00 AM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BAUSCH HEALTH ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2025 RESULTS

    Fourth Quarter Consolidated Revenues of $2.80 billion, up 9% on a Reported basis and up 6% on an Organic (non-GAAP)1 basis over the prior year periodFull-Year Consolidated Revenues of $10.27 billion, up 7% on a Reported basis and 5% on an Organic (non-GAAP)1 basisGAAP Net Loss Attributable to Bausch Health of $112 million for the quarter and GAAP Net Income Attributable to Bausch Health of $157 million for the yearConsolidated Adjusted EBITDA Attributable to Bausch Health (non-GAAP)1 of $1.05 billion for the quarter, up 13%, and $3.54 billion for the year, up 7%BAUSCH HEALTH EXCLUDING BAUSCH + LOMB FOURTH QUARTER AND FULL-YEAR 2025 RESULTSDelivered eleventh consecutive quarter of year-over-y

    2/18/26 4:05:00 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Bausch Health Companies Inc.

    SC 13G - Bausch Health Companies Inc. (0000885590) (Subject)

    8/30/24 6:12:52 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Bausch Health Companies Inc.

    SC 13D/A - Bausch Health Companies Inc. (0000885590) (Subject)

    8/19/24 5:48:41 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Bausch Health Companies Inc. (Amendment)

    SC 13G/A - Bausch Health Companies Inc. (0000885590) (Subject)

    2/13/24 4:30:26 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care